Stocks News

LAST PRICE
258.1300
TODAY'S CHANGE (%)
Trending Up2.9900 (1.1719%)

Bid / Lots
220.0000/ 1
Ask / Lots
296.5600/ 1
Open / Previous Close
255.1000 / 255.1400
Day Range
Low 253.9300
High 260.3400
52 Week Range
Low 204.4400
High 261.5400
Volume
717,192
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Today
- UBS Adjusts Price Target on United Therapeutics to $300 From $290, Maintains Buy Rating, from 6 hours ago by MT Newswires
  6 hours ago by MT Newswires
  Companies Mentioned: UTHR
  11:35 AM EDT, 05/02/2024 (MT Newswires) -- United Therapeutics (UTHR) has an average outperform rating and a price target range of $218 to $400, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research...
- Oppenheimer Adjusts United Therapeutics Price Target to $400 From $375, Maintains Outperform Rating, from 8 hours ago by MT Newswires
  8 hours ago by MT Newswires
  Companies Mentioned: UTHR
  09:54 AM EDT, 05/02/2024 (MT Newswires) -- United Therapeutics (UTHR) has an average rating of outperform and price targets ranging from $218 to $400, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic re...
- DJ United Therapeutics Is Maintained at Outperform by Oppenheimer, from 9 hours ago by Dow Jones
  9 hours ago by Dow Jones
  Companies Mentioned: UTHR
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/UTHR/analyst-ratings
  
  (END) Dow Jones Newswires
  
  May 02, 2024 09:10 ET (13:10 GMT)
- DJ United Therapeutics Price Target Maintained With a $300.00/Share by HC Wainwright & Co., from 11 hours ago by Dow Jones
  11 hours ago by Dow Jones
  Companies Mentioned: UTHR
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/UTHR/analyst-ratings
  
  (END) Dow Jones Newswires
  
  May 02, 2024 07:07 ET (11:07 GMT)
Yesterday
- DJ United Therapeutics Up Over 8%, on Pace for Largest Percent Increase Since November 2022 -- Data Talk, from 2:56PM ET on Wednesday May 01, 2024 by Dow Jones
  2:56PM ET on Wednesday May 01, 2024 by Dow Jones
  Companies Mentioned: UTHR
  
  United Therapeutics Corporation ( UTHR ) is currently at $253.83, up $19.50 or 8.32%
  
  --Would be highest close since Dec. 14, 2023, when it closed at $254.09

Yesterday
- Medpace Holdings Insider Sold Shares Worth $6,782,987, According to a Recent SEC Filing, from 4:59PM ET on Wednesday May 01, 2024 by MT Newswires
  4:59PM ET on Wednesday May 01, 2024 by MT Newswires
  Companies Mentioned: MEDP
- Exact Sciences to Participate in May Investor Conference, from 6:00AM ET on Wednesday May 01, 2024 by Business Wire
  6:00AM ET on Wednesday May 01, 2024 by Business Wire
  Companies Mentioned: EXAS
Apr 29, 2024
- Qiagen Q1 Adjusted Earnings, Sales Decline; Q2 Outlook Issued, 2024 Guidance Affirms -- Shares Fall After Hours, from 4:48PM ET on Monday Apr 29, 2024 by MT Newswires
  4:48PM ET on Monday Apr 29, 2024 by MT Newswires
  Companies Mentioned: QGEN
- BioMarin Pharmaceutical Investors Overfocused on Roctavian, Distracted From Enzyme Replacement Therapies, UBS Says, from 2:26PM ET on Monday Apr 29, 2024 by MT Newswires
  2:26PM ET on Monday Apr 29, 2024 by MT Newswires
  Companies Mentioned: BMRN
Apr 25, 2024
- Scotiabank Adjusts Price Target on BioMarin Pharmaceutical to $83 From $85, Maintains Sector Perform Rating, from 11:43AM ET on Thursday Apr 25, 2024 by MT Newswires
  11:43AM ET on Thursday Apr 25, 2024 by MT Newswires
  Companies Mentioned: BMRN
- Wells Fargo Adjusts Price Target on BioMarin Pharmaceutical to $110 From $100, Maintains Overweight Rating, from 10:31AM ET on Thursday Apr 25, 2024 by MT Newswires
  10:31AM ET on Thursday Apr 25, 2024 by MT Newswires
  Companies Mentioned: BMRN
Apr 24, 2024
- BioMarin Pharmaceutical Q1 Non-GAAP EPS, Revenue Increase -- Shares Down After Hours, from 4:23PM ET on Wednesday Apr 24, 2024 by MT Newswires
  4:23PM ET on Wednesday Apr 24, 2024 by MT Newswires
  Companies Mentioned: BMRN
- -- GUIDANCE: (BMRN) BIOMARIN PHARMACEUTICAL Forecasts Fiscal Year 2024 EPS Range $2.75 - $2.95, from 4:05PM ET on Wednesday Apr 24, 2024 by MT Newswires
  4:05PM ET on Wednesday Apr 24, 2024 by MT Newswires
  Companies Mentioned: BMRN
- -- Earnings Flash (BMRN) BIOMARIN PHARMACEUTICAL Posts Q1 Revenue $648.8M, from 4:04PM ET on Wednesday Apr 24, 2024 by MT Newswires
  4:04PM ET on Wednesday Apr 24, 2024 by MT Newswires
  Companies Mentioned: BMRN
- -- Earnings Flash (BMRN) BIOMARIN PHARMACEUTICAL Posts Q1 EPS $0.71, from 4:04PM ET on Wednesday Apr 24, 2024 by MT Newswires
  4:04PM ET on Wednesday Apr 24, 2024 by MT Newswires
  Companies Mentioned: BMRN

United Therapeutics Corp
NASDAQ:UTHRUnited States

Search Criteria

Today

UBS Adjusts Price Target on United Therapeutics to $300 From $290, Maintains Buy Rating, from 6 hours ago by MT Newswires

Oppenheimer Adjusts United Therapeutics Price Target to $400 From $375, Maintains Outperform Rating, from 8 hours ago by MT Newswires

DJ United Therapeutics Is Maintained at Outperform by Oppenheimer, from 9 hours ago by Dow Jones

DJ United Therapeutics Price Target Maintained With a $300.00/Share by HC Wainwright & Co., from 11 hours ago by Dow Jones

Yesterday

DJ United Therapeutics Up Over 8%, on Pace for Largest Percent Increase Since November 2022 -- Data Talk, from 2:56PM ET on Wednesday May 01, 2024 by Dow Jones

Peers Headlines

Yesterday

Medpace Holdings Insider Sold Shares Worth $6,782,987, According to a Recent SEC Filing, from 4:59PM ET on Wednesday May 01, 2024 by MT Newswires

Exact Sciences to Participate in May Investor Conference, from 6:00AM ET on Wednesday May 01, 2024 by Business Wire

Apr 29, 2024

Qiagen Q1 Adjusted Earnings, Sales Decline; Q2 Outlook Issued, 2024 Guidance Affirms -- Shares Fall After Hours, from 4:48PM ET on Monday Apr 29, 2024 by MT Newswires

BioMarin Pharmaceutical Investors Overfocused on Roctavian, Distracted From Enzyme Replacement Therapies, UBS Says, from 2:26PM ET on Monday Apr 29, 2024 by MT Newswires

Apr 25, 2024

Scotiabank Adjusts Price Target on BioMarin Pharmaceutical to $83 From $85, Maintains Sector Perform Rating, from 11:43AM ET on Thursday Apr 25, 2024 by MT Newswires

Wells Fargo Adjusts Price Target on BioMarin Pharmaceutical to $110 From $100, Maintains Overweight Rating, from 10:31AM ET on Thursday Apr 25, 2024 by MT Newswires

Apr 24, 2024

BioMarin Pharmaceutical Q1 Non-GAAP EPS, Revenue Increase -- Shares Down After Hours, from 4:23PM ET on Wednesday Apr 24, 2024 by MT Newswires

-- GUIDANCE: (BMRN) BIOMARIN PHARMACEUTICAL Forecasts Fiscal Year 2024 EPS Range $2.75 - $2.95, from 4:05PM ET on Wednesday Apr 24, 2024 by MT Newswires

-- Earnings Flash (BMRN) BIOMARIN PHARMACEUTICAL Posts Q1 Revenue $648.8M, from 4:04PM ET on Wednesday Apr 24, 2024 by MT Newswires

-- Earnings Flash (BMRN) BIOMARIN PHARMACEUTICAL Posts Q1 EPS $0.71, from 4:04PM ET on Wednesday Apr 24, 2024 by MT Newswires